CHF Solutions Announces Webinar on Pediatric Ultrafiltration Therapy hosted by Ladenburg Thalman & Co.
December 04 2020 - 8:00AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
changing the lives of patients suffering from fluid overload, today
announced that Ladenburg Thalman & Co. will host a conference
call and webcast at 1:00p.m. Eastern Time on Tuesday, December 8,
2020 highlighting pediatric ultrafiltration therapy and the Aquadex
SmartFlow™ System as part of Ladenburg Thalman’s LT Healthcare
Symposia Series.
Speakers include Dr. David Askenazi, M.D. MSPH, Director of the
Pediatric and Infant Center for Acute Nephrology at Children’s of
Alabama, University of Alabama-Birmingham, and Dr. Scott
Sutherland, Pediatric Nephrologist at Lucile Packard Children’s
Hospital and Clinical Professor of Pediatrics and Nephrology,
Stanford University. Jeff Cohen, Managing Director, Equity Research
at Ladenburg Thalmann & Co., will be moderating the
discussion.
To register for the conference call and webcast, please visit
https://zoom.us/webinar/register/WN_aTBb91xqTmaa5-2ttrWn9g.
About CHF Solutions CHF Solutions, Inc.
(Nasdaq: CHFS) is a medical device company dedicated to improving
the lives of patients suffering from fluid overload with its novel
ultrafiltration therapy system. The company is focused on
developing, manufacturing and commercializing the Aquadex SmartFlow
system for ultrafiltration therapy. CHF Solutions is headquartered
in Minneapolis, Minn., with wholly-owned subsidiaries in Australia
and Ireland. The company has been listed on the Nasdaq Capital
Market since February 2012.
About the Aquadex SmartFlow System The Aquadex
SmartFlow system delivers clinically proven therapy using a simple,
flexible and smart method of removing excess fluid from patients
suffering from hypervolemia (fluid overload). The Aquadex SmartFlow
system is indicated for temporary (up to 8 hours) or extended
(longer than 8 hours in patients who require hospitalization) use
in adult and pediatric patients weighing 20 kg or more whose fluid
overload is unresponsive to medical management, including
diuretics. All treatments must be administered by a health care
provider, within an outpatient or inpatient clinical setting, under
physician prescription, both having received training in
extracorporeal therapies.
Forward-Looking Statements Certain statements
in this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements regarding the use of
the Aquadex SmartFlow system to treat pediatric patients.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our ability to execute on our commercial strategy, the possibility
that we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS
INVESTORS:Claudia Napal Drayton Chief Financial
Officer, CHF Solutions, Inc. 952-345-4205ir@chf-solutions.com
Matt Bacso, CFAGilmartin Group
LLCMatt.bacso@gilmartinir.com
MEDIA:Jessica
StebingHealth+Commerce260-336-6202jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024